Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2009, Article ID 672178, 6 pages
http://dx.doi.org/10.1155/2009/672178
Clinical Study

Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema

1Department of Ophthalmology, Ospedali Riuniti, University of Foggia, Viale Pinto, 1 71100, Foggia, Italy
2Department of Hygiene, Policlinico di Bari, University of Bari, 70127 Bari, Italy

Received 19 August 2009; Accepted 2 December 2009

Academic Editor: Peter J. Francis

Copyright © 2009 G. Querques et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B Richter and E. Kohner, “Medical interventions for diabetic retinopathy,” in Evidence-Based Ophthalmology, R Wormald, L. Smeeth, and K. Henshaw, Eds., pp. 331–40, BMJ Books, London, UK, 2004. View at Google Scholar
  2. T. A. Ciulla, A. G. Amador, and B. Zinman, “Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies,” Diabetes Care, vol. 26, no. 9, pp. 2653–2664, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Antcliff and J. Marshall, “The pathogenesis of edema in diabetic maculopathy,” Seminars in Ophthalmology, vol. 14, no. 4, pp. 223–232, 1999. View at Google Scholar · View at Scopus
  4. A. Patz, T. A. Rice, and R. P. Murphy, “Photocoagulation for diabetic macular edema,” Archives of Ophthalmology, vol. 103, no. 12, pp. 1796–1806, 1985. View at Google Scholar · View at Scopus
  5. F. Bandello, P. Lanzetta, and U. Menchini, “When and how to do a grid laser for diabetic macular edema,” Documenta Ophthalmologica, vol. 97, no. 3-4, pp. 415–419, 1999. View at Google Scholar · View at Scopus
  6. Early Treatment Diabetic Retinopathy Study Research Group, “Early photocoagulation for diabetic retinopathy. ETDRS report number 9,” Ophthalmology, vol. 98, supplement 5, pp. 766–785, 1991. View at Google Scholar
  7. F. K. P. Sutter, J. M. Simpson, and M. C. Gillies, “Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial,” Ophthalmology, vol. 111, no. 11, pp. 2044–2049, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. P. Massin, F. Audren, B. Haouchine et al., “Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial,” Ophthalmology, vol. 111, no. 2, pp. 218–224, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. C. Gillies, F. K. P. Sutter, J. M. Simpson, J. Larsson, H. Ali, and M. Zhu, “Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial,” Ophthalmology, vol. 113, no. 9, pp. 1533–1538, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. J. B. Jonas, B. A. Kamppeter, B. Harder, U. Vossmerbaeumer, G. Sauder, and U. H. M. Spandau, “Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study,” Journal of Ocular Pharmacology and Therapeutics, vol. 22, no. 3, pp. 200–207, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. F. Audren, A. Erginay, B. Haouchine et al., “Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial,” Acta Ophthalmologica Scandinavica, vol. 84, no. 5, pp. 624–630, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. B. Katz, “A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema,” Ophthalmology, vol. 112, no. 10, pp. 1747–1757, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. D. W. Chun, J. S. Heier, T. M. Topping, J. S. Duker, and J. M. Bankert, “A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema,” Ophthalmology, vol. 113, no. 10, pp. 1706–1712, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. C. Haritoglou, D. Kook, A. Neubauer et al., “Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema,” Retina, vol. 26, no. 9, pp. 999–1005, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. C. Starita, M. Patel, B. Katz, and A. Adamis, “Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen®) in diabetic retinopathy,” Developments in Ophthalmology, vol. 39, pp. 122–148, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. D. A. Antonetti, E. B. Wolpert, L. DeMaio, N. S. Harhaj, and R. C. Scaduto Jr., “Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin,” Journal of Neurochemistry, vol. 80, no. 4, pp. 667–677, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. T. W. Gardner, D. A. Antonetti, A. J. Barber, K. F. LaNoue, and S. W. Levison, “Diabetic retinopathy: more than meets the eye,” Survey of Ophthalmology, vol. 47, supplement 2, pp. S253–S262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. L. P. Aiello, “Angiogenic pathways in diabetic retinopathy,” The New England Journal of Medicine, vol. 353, no. 8, pp. 839–841, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, “Pegaptanib for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2805–2816, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. N. Ferrara, K. J. Hillan, H.-P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Google Scholar · View at Scopus
  21. R. F. Spaide and Y. L. Fisher, “Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage,” Retina, vol. 26, no. 3, pp. 275–278, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. D. Iturralde, R. F. Spaide, C. B. Meyerle et al., “Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study,” Retina, vol. 26, no. 3, pp. 279–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. F. Arevalo, J. Fromow-Guerra, H. Quiroz-Mercado et al., “Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Results from the pan-american collaborative retina study group at 6-month follow-up,” Ophthalmology, vol. 114, no. 4, pp. 743–750, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Diabetic Retinopathy Clinical Research Network, I. U. Scott, A. R. Edwards et al., “A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema,” Ophthalmology, vol. 114, no. 10, pp. 1860–1867, 2007. View at Google Scholar
  27. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. D. W. Drolet, J. Nelson, C. E. Tucker et al., “Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys,” Pharmaceutical Research, vol. 17, no. 12, pp. 1503–1510, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Thompson and M. S. Ip, “Diabetic macular edema: a review of past, present, and future therapies,” International Ophthalmology Clinics, vol. 44, no. 4, pp. 51–67, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Christoforidis and D. J. D'Amico, “Surgical and other treatments of diabetic macular edema: an update,” International Ophthalmology Clinics, vol. 44, no. 1, pp. 139–160, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. R. B. Bhisitkul, “Vascular endothelial growth factor biology: clinical implications for ocular treatments,” British Journal of Ophthalmology, vol. 90, no. 12, pp. 1542–1547, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. M. C. Gillies, “What we don't know about avastin might hurt us,” Archives of Ophthalmology, vol. 124, no. 10, pp. 1478–1479, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus